Novel Fluorinated Glucosamine Analogs for the Treatment of Multiple Sclerosis

Life & Medical Sciences Therapeutics
Tech ID #: 628.12 

Dr. Wee Yong, Dr. Chang-Chun Ling, and collaborators at the University of Calgary have generated a series of small molecules that inhibit the production of chondroitin sulfate proteoglycans (CSPGs). In neurological disorders like multiple sclerosis, CSPGs are upregulated, which increases the immune response and acts as a barrier to remyelination. The novel glucosamine compounds are able to enhance oligodendrocyte precursor cell (OPC) growth, reduce T cell proliferation, and reduce CSPG production. Experimental autoimmune encephalomyelitis (EAE) mice that were given the compounds showed reduced EAE clinical severity. 



  • Multiple sclerosis 
  • Other potential areas of application:  
  • Alzheimer’s disease 
  • Traumatic brain injury   
  • Stroke 
  • Amyotrophic lateral sclerosis  
  • Huntington’s disease  
  • Parkinson’s disease   
  • Neuroinflammatory diseases  



  • A problem with current promising therapies for MS is that once CSPG is anchored onto a substrate, the CSPG inhibition of the morphological differentiation of OPCs cannot be reversed 
  • This technology:   
  • Inhibits CSPG biosynthesis and enables natural remyelination to take place  
  • The newly discovered compounds display greater potency and efficacy than current compounds in blocking CSPG biosynthesis 



  • Pre-clinical: In vitro and in vivo testing has been carried out 
  • Seeking a partnership for further pre-clinical validation of compounds   





Questions? Need more information?

Reach out and connect. Our tech transfer team is ready to help.

Contact Us